Semaglutide can help the body make more insulin and improves insulin sensitivity, which in turn lowers blood-glucose levels ...

Real-world data show semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are linked with lower risk of major ...

Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an accep ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced ...

Learn about semaglutide’s effectiveness and clinical trial results and whether it could be right for you in your MASH ...

At present, around 59 million adults worldwide have diabetes, about 64 million are diagnosed with heart failure, and ...

Medications like Ozempic mimic a naturally occurring hormone called glucagon-like peptide-1, or GLP-1, which helps regulate blood sugar and appetite. GLP-1 is primarily secreted from the intestines, ...

Novo, however, vastly underestimated the appetite for its new weight-loss jab. Mr Doustdar says it planned for demand to be three times that of Saxenda, an older and less-effective weight-loss drug.

Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

Aviceda Therapeutics ("the Company" or "Aviceda"), a clinical-stage biotechnology company developing innovative therapies for retinal diseases, today announced topline results from its SIGLEC Phase 2b ...

The MarketWatch News Department was not involved in the creation of this content.-- Wegovy(R) (semaglutide injection) granted conditional marketing authorization for the treatment ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...